9AU16117

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

OIPE

JUL 2 2 1999

IN THE APPLICATION OF:

He, et al.

SERIAL NO.: 09/015,002

FILED: JANUARY 28,

FOR: AZOLO TRIAZINES AND PYRIMIDINES !

CASE NO.: DM-6864-A

GROUP ART UNIT: 1611 RECEIVED

EXAMINER: Ford, J.

TECH CENTER 1600/29

Wilmington, Delaware July 20, 1999

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Hon. Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56 (b). Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

The references cited Supplemental in this submitted Disclosure Statement were Information with the Disclosure Statement filed on February 18, 1999. However, because the year of publication of each of the cited references was not included in the original Information Disclosure Statement, the Examiner did not initial them as having been reviewed. In this Supplemental Information Disclosure Statement, Applicants are resubmitting those references including the year of publication for each reference. Applicants respectfully request review of the references provided in the Supplemental Information Disclosure Statement by the Examiner.

07/27/1999 AIBRAHIN 00000174 041928 09015002

01 FC:126 240.00 CH DM-6864-A / USSN 09/015,002 Supplemental IDS July 20, 1999

In accordance with \$1.97(c), this Supplemental Information Disclosure Statement is being filed after the period set forth in \$1.97(b) above but before the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under \$1.311. Therefore, The fee of \$220.00 as set forth in \$1.7(p) should be charged to Deposit Account No. 04-1928.

Respectfully submitted,

Marrier P. O'Brien

Maureen P. O'Brien, Ph.D., J.D.

Attorney for Agent

Registration No.: 42,043 Telephone: 302-992-4528

DuPont Pharmaceuticals Company c/o. Legal-Patents 1007 Market Street Wilmington, Delaware

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Hon. Assistant Commissioner for Patents, Washington, D.C. 20231 on Quy 10, 1999

Cathlun M. Glins
Cathleen M. Collins